IDiyas

For the Inventor, By the Inventor

Fanwood, NJ, United States of America

Pengcheng Patrick Shao

USPTO Granted Patents = 12 

 

 

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 29(Granted Patents)


Company Filing History:

goldMedal12 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents

Years Active: 2012-2025

where 'Filed Patents' based on already Granted Patents

12 patents (USPTO):
1. 12440496 - Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes (2025-10-14),
2. 10508108 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-12-17),
3. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),
4. 10086000 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2018-10-02),
5. 10011572 - Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein (2018-07-03),
6. 9981970 - Bicyclic ureas and thiadiazolidine-1, 1-dioxides as CETP inhibitors (2018-05-29),
7. 9663534 - Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein (2017-05-30),
8. 9580396 - C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use (2017-02-28),
9. 9376408 - Therapeutic thiazolidinone compounds (2016-06-28),
10. 9346825 - Fused bicyclic oxazolidinone CETP inhibitor (2016-05-24),
11. 8871738 - Fused bicyclic oxazolidinone CETP inhibitor (2014-10-28),
12. 8304434 - Substituted aryl sulfone derivatives as calcium channel blockers (2012-11-06),

Title: Innovations of Pengcheng Patrick Shao

Introduction

Pengcheng Patrick Shao is a prominent inventor based in Fanwood, NJ, with a remarkable portfolio of 12 patents. His work primarily focuses on developing innovative compounds for the treatment of various diseases, including cardiometabolic conditions and cancers.

Latest Patents

Among his latest patents is the invention of natriuretic peptide receptor A agonists, which are useful for treating cardiometabolic diseases, kidney disease, and diabetes. This invention relates to compounds of Formula I and their pharmaceutically acceptable salts or prodrugs. The invention also includes compositions comprising at least one compound of Formula I and methods for using these compounds to treat conditions such as high blood pressure, heart failure, kidney disease, and diabetes. Another significant patent involves tricyclic compounds as inhibitors of mutant IDH enzymes. This invention is directed to tricyclic compounds of formula (I) that inhibit one or more mutant IDH enzymes. The patent also discusses the potential treatment or prevention of cancers associated with these enzymes.

Career Highlights

Pengcheng Patrick Shao is currently associated with Merck Sharp & Dohme Corporation, where he contributes to groundbreaking research and development in the pharmaceutical field. His innovative approach and dedication to improving health outcomes have made him a valuable asset to the company.

Collaborations

He has collaborated with notable coworkers, including Feng Ye and Petr Vachal, to advance research initiatives and develop new therapeutic solutions.

Conclusion

Pengcheng Patrick Shao's contributions to the field of medicine through his patents and collaborations highlight his commitment to innovation and improving patient care. His work continues to pave the way for advancements in the treatment of complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…